- Home
- URGN vs VEL Comparison
URGN vs VEL Comparison
Compare URGN & VEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | URGN | VEL |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 922.1M | 768.3M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | URGN | VEL |
|---|---|---|
| Price | $18.44 | $17.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $29.29 | $22.00 |
| AVG Volume (30 Days) | ★ 816.7K | 95.6K |
| Earning Date | 06-10-2026 | 06-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.98 |
| EPS | N/A | ★ 2.75 |
| Revenue | ★ $1,128,000.00 | N/A |
| Revenue This Year | $119.37 | $5.75 |
| Revenue Next Year | $64.79 | $27.31 |
| P/E Ratio | ★ N/A | $6.47 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.42 | $16.12 |
| 52 Week High | $30.00 | $21.40 |
Technical Indicators
Market Signals| Indicator | URGN | VEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 33.24 |
| Support Level | $16.47 | $16.19 |
| Resistance Level | $20.44 | $19.37 |
| Average True Range (ATR) | 1.45 | 0.57 |
| MACD | -0.18 | -0.07 |
| Stochastic Oscillator | 13.89 | 5.20 |
Price Performance
Historical ComparisonAbout URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.